Jan Leschly: This One Didn't Clear The Net

Jan Leschly is on the defensive. Following the acrimonious Feb. 23 collapse of merger talks between SmithKline Beecham and Glaxo Wellcome, Leschly, a tennis pro turned SmithKline CEO, is under pressure from investors to get a deal.

Leschly nixed the Glaxo deal after a Feb. 20 meeting with Glaxo CEO Richard Sykes in which, a former SB insider says, the exec discovered that the proposed combination was "not a merger, but a takeover." But investors were upset that the deal had come apart: They knocked SmithKline's value down by $6.6 billion.

SmithKline is profitable--earnings rose 17%, to $2.7 billion, in 1997--but it ranks ninth in prescription-drug sales, down from third in 1989. And while its investments have turned up many leads for new drugs, SmithKline lacks the R&D funds to pursue all of them.

Roche Holdings, Schering-Plough, Warner-Lambert, and Britain's Zeneca are all possible partners. Now, Leschly, 57, has to prove he can fight back from two sets down.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE